RxDoctor Payments DataLook up a doctor →

Anjaneyulu Alapati, MD

Neurology · Huntsville, ALNPI 1992791297

Payments from drug & device makers

$133,291in general payments, 2019–2025

Across 1,816 payments — averaging $73.40 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • SK Life Science, Inc.$45K
  • UCB, Inc.$39K
  • Eisai Inc.$12K
  • AbbVie$5K
  • Novartis$5K
  • Catalyst Pharmaceuticals, Inc.$4K
  • plus $24K from 54 others

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
SK Life Science, Inc.112$44,773
UCB, Inc.366$38,591
Eisai Inc.53$11,588
AbbVie(2 entities)148$4,886
Novartis103$4,580
Catalyst Pharmaceuticals, Inc.34$4,221
Argenx US, Inc.40$3,233
Acadia Pharmaceuticals Inc28$2,878
AstraZeneca54$1,201
Amgen(2 entities)58$1,145
Genentech USA, Inc.67$1,112
Sanofi33$1,065
Lilly USA, LLC53$920
Neurocrine Biosciences, Inc.47$884
Johnson & Johnson(2 entities)42$869
Biogen44$720
Bristol Myers Squibb29$675
Teva Pharmaceuticals USA, Inc.33$635
Sunovion Pharmaceuticals Inc.36$549
Supernus Pharmaceuticals, Inc.40$532
Novo Nordisk5$497
EMD Serono, Inc.25$495
TG Therapeutics, Inc.23$477
Neurelis, Inc.25$459
Pfizer31$443
MDD US Operations, LLC15$438
Jazz Pharmaceuticals Inc.20$425
Acorda Therapeutics, Inc20$403
Grifols USA, LLC24$401
Aquestive Therapeutics, Inc.9$397
Avanir Pharmaceuticals, Inc.22$378
Adamas Pharmaceuticals, Inc.20$361
Lundbeck LLC21$351
Sumitomo Pharma America, Inc.12$285
Otsuka America Pharmaceutical, Inc.9$231
Axsome Therapeutics, Inc.4$179
Aucta Pharmaceuticals, Inc.7$157
Merz Pharmaceuticals, LLC8$153
Scilex Pharmaceuticals Inc.7$123
Greenwich Biosciences, Inc.6$120
Amneal Pharmaceuticals LLC8$113
Takeda Pharmaceuticals U.S.A., Inc.5$105
Biohaven Pharmaceutical Holding Company Ltd.4$101
Banner Life Sciences, LLC5$78
Vanda Pharmaceuticals Inc.3$70
E.r. Squibb & Sons, L.L.C.5$62
GE HealthCare3$62
Kyowa Kirin, Inc.4$61
Impel Pharmaceuticals Inc.3$59
Livanova USA, Inc.4$54
Upsher-smith Laboratories LLC3$51
Mallinckrodt Hospital Products Inc.2$49
Currax Pharmaceuticals LLC3$43
Akcea Therapeutics, Inc.2$42
Zogenix Inc.3$41
Abbott1$41
Xeris Pharmaceuticals, Inc.2$38
ANI Pharmaceuticals, Inc.1$35
Biohaven Pharmaceuticals, Inc.2$35
Boston Scientific3$34

How this compares

$133,291 in reported general payments places this provider in the 85th percentile of 255 neurology providers in Alabama.

See all neurology providers in Alabama →

Medicare billing

Part B allowed, 2024
$316,829
Medicare patients
1,242
Services billed
4,396

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Other neurology in Huntsville

See the full list for Alabama →

Where these figures come from

Is this you, or does something look wrong? →